Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle Mass on Long-Lasting Post-Vaccinal Immunity.
BNT162 vaccine
COVID-19
COVID-19 vaccine
IgG antibody
SARS-CoV-2
adipose tissue
body composition
health care professionals
healthcare workers
immunization
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
22 04 2022
22 04 2022
Historique:
received:
22
03
2022
revised:
15
04
2022
accepted:
19
04
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
This study aimed to investigate the early and longitudinal humoral response in Healthcare Workers (HCWs) after two doses of the BNT162b2 vaccine and to assess the association between metabolic and anthropometric parameters and the humoral response after vaccination. The study included 243 fully vaccinated HCWs: 25.50% previously infected with SARS-CoV-2 (with prior history of COVID-19-PH) and 74.40%-uninfected, seronegative before the first vaccination (with no prior history of COVID-19-NPH). IgG antibodies were measured, and sera were collected: prior to the vaccination, 21 days after the first dose, and 14 days and 8 months after the second dose. 21 days after the first dose, 90.95% of individuals were seropositive; 14 days after the second dose, persistent immunity was observed in 99.18% HCWs, 8 months after complete vaccination-in 61.73%. Statistical analysis revealed that HCWs with PH had a greater chance of maintaining a humoral response beyond eight months after vaccination. Increased muscle mass, decreased fat mass, and younger age may positively affect long-term immunity. Smokers have a reduced chance of developing immunity compared to non-smokers. Fully vaccinated HCWs with PH are more likely to be seropositive than fully inoculated volunteers with NPH.
Sections du résumé
BACKGROUND
This study aimed to investigate the early and longitudinal humoral response in Healthcare Workers (HCWs) after two doses of the BNT162b2 vaccine and to assess the association between metabolic and anthropometric parameters and the humoral response after vaccination.
METHODS
The study included 243 fully vaccinated HCWs: 25.50% previously infected with SARS-CoV-2 (with prior history of COVID-19-PH) and 74.40%-uninfected, seronegative before the first vaccination (with no prior history of COVID-19-NPH). IgG antibodies were measured, and sera were collected: prior to the vaccination, 21 days after the first dose, and 14 days and 8 months after the second dose.
RESULTS
21 days after the first dose, 90.95% of individuals were seropositive; 14 days after the second dose, persistent immunity was observed in 99.18% HCWs, 8 months after complete vaccination-in 61.73%. Statistical analysis revealed that HCWs with PH had a greater chance of maintaining a humoral response beyond eight months after vaccination. Increased muscle mass, decreased fat mass, and younger age may positively affect long-term immunity. Smokers have a reduced chance of developing immunity compared to non-smokers.
CONCLUSIONS
Fully vaccinated HCWs with PH are more likely to be seropositive than fully inoculated volunteers with NPH.
Identifiants
pubmed: 35632610
pii: v14050868
doi: 10.3390/v14050868
pmc: PMC9143881
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
RNA, Messenger
0
Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Annu Rev Immunol. 2012;30:221-41
pubmed: 22224776
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Diabetes Obes Metab. 2013 Sep;15 Suppl 3:34-8
pubmed: 24003919
J Hyg (Lond). 1976 Dec;77(3):409-17
pubmed: 1069819
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
MMWR Morb Mortal Wkly Rep. 2021 Mar 12;70(10):355-361
pubmed: 33705371
Eur J Clin Nutr. 2002 Aug;56 Suppl 3:S42-5
pubmed: 12142961
Oncotarget. 2017 Jan 3;8(1):268-284
pubmed: 27902485
Clin Infect Dis. 2021 Jun 1;72(11):e695-e703
pubmed: 32945846
Trop Med Infect Dis. 2022 Jan 13;7(1):
pubmed: 35051125
Clin Infect Dis. 2020 Jul 28;71(15):884-887
pubmed: 32130405
Vaccines (Basel). 2021 Jul 01;9(7):
pubmed: 34358130
JAMA. 1985 Dec 13;254(22):3187-9
pubmed: 2933532
Antimicrob Steward Healthc Epidemiol. 2021 Oct 21;1(1):e33
pubmed: 36168453
Cytokine. 2001 Apr 21;14(2):121-6
pubmed: 11356013
Front Psychol. 2021 Jul 09;12:631179
pubmed: 34305707
Ann Transl Med. 2020 Apr;8(7):497
pubmed: 32395541
Int J Obes (Lond). 2012 Aug;36(8):1072-7
pubmed: 22024641
Vaccine. 2014 Feb 12;32(8):979-83
pubmed: 24394442
Nutr Today. 2015 May;50(3):117-128
pubmed: 27340299
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Proc Natl Acad Sci U S A. 2020 Jul 28;117(30):17513-17515
pubmed: 32632012
Clin Infect Dis. 2021 Dec 6;73(11):2065-2072
pubmed: 33906236
Obesity (Silver Spring). 2021 Mar;29(3):521-528
pubmed: 33263191
EBioMedicine. 2019 Nov;49:381-388
pubmed: 31662290
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
N Engl J Med. 1986 May 22;314(21):1393
pubmed: 2939347
EClinicalMedicine. 2021 Mar;33:100770
pubmed: 33718853
Diagn Microbiol Infect Dis. 2020 Nov;98(3):115140
pubmed: 32829098
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Proc Nutr Soc. 2012 May;71(2):332-8
pubmed: 22429824
Ann Am Thorac Soc. 2017 Nov;14(Supplement_5):S406-S409
pubmed: 29161078
Int J Mol Med. 2021 Nov;48(5):
pubmed: 34515322
N Engl J Med. 2022 Feb 3;386(5):492-494
pubmed: 34965337
Eur J Clin Invest. 2020 Oct;50(10):e13362
pubmed: 32726868
Nature. 2020 Oct;586(7830):488-489
pubmed: 33082543
Lancet. 2022 Jan 15;399(10321):234-236
pubmed: 34942101
J Med Virol. 2021 Jan;93(1):250-256
pubmed: 32592501
Obesity (Silver Spring). 2016 Mar;24(3):615-25
pubmed: 26857091
Obes Rev. 2021 Jun;22(6):e13216
pubmed: 33719175
Obesity (Silver Spring). 2021 Oct;29(10):1575-1579
pubmed: 34212511
Curr Obes Rep. 2021 Sep;10(3):282-289
pubmed: 34374955
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
J Med Virol. 2022 Apr;94(4):1428-1441
pubmed: 34783055
Nutrition. 2001 Jan;17(1):26-30
pubmed: 11165884
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Int J Mol Sci. 2021 Jul 26;22(15):
pubmed: 34360741
Lancet Reg Health Eur. 2021 Sep;8:100171
pubmed: 34278372
Front Aging. 2020 Oct 15;1:602108
pubmed: 35822168
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Infect Dis Poverty. 2021 Nov 14;10(1):132
pubmed: 34776011
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Clin Biochem. 2021 Apr;90:15-22
pubmed: 33539808
Tob Induc Dis. 2020 Mar 20;18:20
pubmed: 32206052
Int J Environ Res Public Health. 2020 Jul 04;17(13):
pubmed: 32635439
Hastings Cent Rep. 2020 May;50(3):61-63
pubmed: 32596888
Sci Rep. 2021 Dec 30;11(1):24503
pubmed: 34969967
Respir Res. 2020 Aug 27;21(1):224
pubmed: 32854739
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
Nat Microbiol. 2022 Mar;7(3):379-385
pubmed: 35132198
Vaccines (Basel). 2021 Sep 18;9(9):
pubmed: 34579279
Front Immunol. 2019 May 09;10:1076
pubmed: 31156632